Preclinical Characterization of the Radioimmunoconjugate (111)In or (90)Y-FF-21101 Against a P-Cadherin–Expressing Tumor in a Mouse Xenograft Model and a Nonhuman Primate

P-cadherin is overexpressed in various cancers and can be a target for radioimmunotherapy. We investigated the preclinical pharmacokinetics and pharmacology of FF-21101, an (111)In- or (90)Y-conjugated monoclonal antibody against P-cadherin, to evaluate its clinical applications. Methods: The radioc...

Descripción completa

Detalles Bibliográficos
Autores principales: Funase, Yuichi, Nakamura, Eri, Kajita, Masamichi, Saito, Yasutaka, Oshikiri, Shinobu, Kitano, Michi, Tokura, Masahiko, Hino, Akihiro, Uehara, Tomoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2021
Materias:
Theranostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679590/
https://www.ncbi.nlm.nih.gov/pubmed/32737245
http://dx.doi.org/10.2967/jnumed.120.245837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679590/
https://www.ncbi.nlm.nih.gov/pubmed/32737245
http://dx.doi.org/10.2967/jnumed.120.245837

Ejemplares similares